cytokine-storm-analysis-agent

Core Capabilities

1. CRS Risk Prediction: ML models predict CRS development and severity from baseline factors (tumor burden, disease type, CAR-T product).

2. Real-Time Monitoring: Track cytokine dynamics (IL-6, IFN-γ, IL-10, ferritin) with early warning alerts.

3. Severity Grading: Automated ASTCT CRS grading using clinical parameters and biomarkers.

4. Differential Diagnosis: Distinguish CRS from HLH/MAS, ICANS, infection, and tumor lysis syndrome.

5. Treatment Guidance: AI-driven recommendations for tocilizumab, corticosteroids, and supportive care.

6. Outcome Prediction: Model response to anti-cytokine therapy and overall outcomes.

Cytokine Panel Analysis

Cytokine	Role in CRS	Kinetics	Therapeutic Target
IL-6	Central mediator	Early peak	Tocilizumab, Siltuximab
IFN-γ	T-cell activation	Early	Emapalumab
IL-1β	Inflammasome	Early	Anakinra
IL-10	Regulatory	Variable	-
TNF-α	Pro-inflammatory	Early	Infliximab (caution)
IL-2	T-cell expansion	Early	-
GM-CSF	Myeloid activation	Sustained	Lenzilumab

ASTCT CRS Grading (Automated)

Grade	Fever	Hypotension	Hypoxia
1	≥38°C	None	None
2	≥38°C	Responsive to fluids	Low-flow O2
3	≥38°C	One vasopressor	High-flow O2
4	≥38°C	Multiple vasopressors	Ventilation